Assistant Professor
Pharmaceutical Sciences and Health Outcomes
Phone: 903-566-6287
Email: cabdullah@uttyler.edu
Building: WTB 344
Department: Pharmacy
Additional Department: Pharmaceutical Sciences and Health Outcomes
Chowdhury Abdullah
Education
• Ph.D. in Pharmaceutical Sciences, 2016
South Dakota State University, Brookings, SD
• Master of Pharmacy in Clinical Pharmacy and Pharmacology, 2012
University of Dhaka, Dhaka, Bangladesh
• Bachelor of Pharmacy in Pharmaceutical Sciences, 2009
University of Dhaka, Dhaka, Bangladesh
Research Experiences
• Instructor – Research
July 2023 – September 2024
Center for Cardiovascular Diseases and Sciences
Department of Pathology and Translational Pathobiology
Louisiana State University Health Sciences Center – Shreveport, Shreveport, LA
• Postdoctoral Research Fellow
May 2016 – June 2023
Center for Cardiovascular Diseases and Sciences
Department of Pathology and Translational Pathobiology
Louisiana State University Health Sciences Center – Shreveport, Shreveport, LA
• Graduate Research Assistant
August 2012 – April 2016
Department of Pharmaceutical Sciences
College of Pharmacy
South Dakota State University, Brookings, SD
Biography
Dr. Chowdhury S. Abdullah is an Assistant Professor in the Department of Pharmaceutical Sciences and Health Outcomes at Fisch College of Pharmacy at The University of Texas at Tyler, where he joined in October 2024. Dr. Abdullah earned his Bachelor of Pharmacy (with Honors) and Master of Pharmacy in Clinical Pharmacy and Pharmacology from the University of Dhaka, Bangladesh. Dr. Abdullah earned his Ph.D. in Pharmaceutical Sciences from South Dakota State University in 2016. Following his doctoral studies, Dr. Abdullah completed extensive postdoctoral training and served as a Research Instructor at LSU Health Sciences Center – Shreveport, where he researched obesity, cardiometabolic syndrome, diabetes, proteotoxicity, drug abuse, and chemotherapy-induced cardiomyopathies, and macrophage functional plasticity in ischemic heart disease.
Dr. Abdullah has published over 25 research articles in peer-reviewed journals and secured multiple competitive grants, including fellowships from the American Heart Association and the Center for Cardiovascular Diseases and Sciences at LSU Health -Shreveport. He received numerous accolades, including Outstanding Postdoctoral Awards from the American Physiology Society Cardiovascular Section and New Investigator Travel Awards from the American Heart Association, International Society for Heart Research – North American Section. He is an active peer reviewer for several high-impact journals—including Circulation, Circulation: Heart Failure, and Journal of the American Heart Association—and has participated in grant review activities for the American Heart Association’s Basic Science Fellowships Committee.
Dr. Abdullah is committed to excellence in teaching and to providing students with research training and mentorship to promote students’ success. He has taught a wide array of courses in Pathology and Physiology to Doctor of Medicine and Allied Health Professional students, consistently receiving high instructional ratings. Dr. Abdullah’s current research program aims to elucidate novel molecular mechanisms that reduce end-organ damage in cardiometabolic diseases and heart failure. His lab utilizes complementary in vitro and in vivo small animal pre-clinical disease models with genetic approaches to discover molecular mechanisms to prevent metabolic abnormalities in heart failures. In his current role at The University of Texas at Tyler, Dr. Abdullah continues to advance his research on cardiometabolic disorders while providing engaged, student-centered education and research mentoring to the next generation of scientists and healthcare professionals.
Professional Services
Grant Reviewer, American Heart Association (AHA) Fellowship Basic Science Committee
Peer Reviewer in Journals including Circulation, Circulation: Heart Failure, Circulation: Cardiovascular Imaging, Journal of the American Heart Association, Arteriosclerosis, Thrombosis, and Vascular Biology, Journal of Cardiovascular Pharmacology, Journal of Pharmacological Sciences
Honors/Awards
Malcolm Feist Postdoctoral Transition Award, Center for Cardiovascular Diseases and Sciences, LSU Health Shreveport (2023)
Emeritus Professor D. Neil Granger Outstanding Postdoctoral Trainee Award, LSU Health – Shreveport (2022)
APS Cardiovascular Section Outstanding Postdoctoral Award (2021)
The Michael Bristow Investigator Travel Award, ISHR – NAS (2021)
AHA BCVS New Investigator Travel Awards (2018, 2015)
AHA Postdoctoral Fellowship (2020-2021)
National Rho Chi Honor Society Member (2015)
Selected Publications
1. Abdullah CS, Remex NS, Aishwarya R, Nitu S, Kolluru GK, Traylor J, Hartman B, King J, Bhuiyan MAN, Hall N, Murnane KS, Goeders NE, Kevil CG, Orr AW, Bhuiyan MS. Mitochondrial dysfunction and autophagy activation are associated with cardiomyopathy developed by extended methamphetamine self-administration in rats. Redox Biol. 2022; 58:102523. PMID: 36335762.
2. Abdullah CS, Aishwarya R, Alam S, Remex NS, Morshed M, Nitu S, Miriyala S, Panchatcharam M, Hartman B, King J, Bhuiyan MAN, Traylor J, Kevil CG, Orr AW, Bhuiyan MS. The molecular role of Sigmar1 in regulating mitochondrial function through mitochondrial localization in cardiomyocytes. Mitochondrion. 2022; 62:159-175. PMID: 34902622.
3. Abdullah CS, Aishwarya R, Alam S, Morshed M, Remex NS, Nitu S, Kolluru GK, Traylor J, Miriyala S, Panchatcharam M, Hartman B, King J, Bhuiyan MAN, Chandran S, Woolard MD, Yu X, Goeders NE, Dominic P, Arnold CL, Stokes K, Kevil CG, Orr AW, Bhuiyan MS. Methamphetamine induces cardiomyopathy by Sigmar1 inhibition-dependent impairment of mitochondrial dynamics and function. Commun Biol. 2020; 3(1):682. PMID: 33203971.
4. Abdullah CS, Alam S, Aishwarya R, Miriyala S, Bhuiyan MAN, Panchatcharam M, Patillo CB, Orr AW, Sadoshima J, Hill JA, Bhuiyan MS. Doxorubicin-induced cardiomyopathy associated with inhibition of autophagic degradation process and defects in mitochondrial respiration. Sci Rep. 2019; 9(1): 2002; PMID: 30765730.
5. Abdullah CS, Alam S, Aishwarya R, Miriyala S, Panchatcharam M, Bhuiyan MAN, Peretik JM, Orr AW, James J, Osinska H, Robbins J, Lorenz JN, Bhuiyan MS. Cardiac dysfunction in the Sigma 1 receptor knockout mouse associated with impaired mitochondrial dynamics and bioenergetics. J Am Heart Assoc. 2018; 7(20): e009775. PMID: 30371279.
6. Remex NS*, Abdullah CS*, Aishwarya R, Nitu SS, Traylor J, Hartman B, King J, Bhuiyan MAN, Kevil CG, Orr AW, Bhuiyan MS. Sigmar1 ablation leads to lung pathological changes associated with pulmonary fibrosis, inflammation and altered surfactant protein levels. Front Physiol. 2023; 14:1118770. PMID: 37051024. *co-first authors
7. Aishwarya R*, Abdullah CS*, Remex NS, Alam S, Morshed M, Nitu S, Hartman B, King J, Bhuiyan MAN, Orr AW, Kevil CG, Bhuiyan MS. Molecular characterization of skeletal muscle dysfunction in Sigma 1 receptor (Sigmar1) knockout mice. Am J Pathol. 2022; 192(1):160-177. PMID: 34710383. *co-first authors
8. Abdullah CS, Jin ZQ. Targeted deletion of T cell S1P receptor 1 renders mouse heart vulnerable to fibrosis in normoglycemia but reduces myocardial fibrosis under hyperglycemia. FASEB J. 2018; 32(10):5426-5435. PMID: 29698062.
9. Abdullah CS, Li Z, Wang X, Jin ZQ. Depletion of T lymphocytes ameliorates cardiac fibrosis in streptozotocin-induced diabetic cardiomyopathy. Int Immunopharmacol. 2016, 39:251-264. PMID: 27494688.